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Purpose: Behcet’s disease (BD) is a multisystemic immunoinflammatory disorder characterized by mucocutaneous,
ocular,  vascular,  and  central  nervous  system  manifestations.  The  common  methylene  tetrahydrofolate  reductase
(MTHFR) gene C677T mutation is a known risk factor for thrombosis. The aim of this study was to investigate the
MTHFR gene C677 mutation in patients with BD and evaluate if there was an association with clinical features, especially
thrombosis, in a relatively large cohort of patients with BD.
Methods: The study included 318 patients with BD and 207 healthy controls. Genomic DNA was isolated and genotyped
using PCR-based restriction fragment length polymorphism assay for the MTHFR gene C677T mutation.
Results: The genotype and allele frequencies of the C677T mutation showed a statistically significant difference between
BD patients and controls (p=0.003 and p=0.001, respectively). There was also a significant association between C677T
alteration and response to colchicine in BD patients (p=0.046).
Conclusions: The results of this study showed that there was a high association between the MTHFR gene C677T mutation
and BD. Stratification analysis according to clinical features for this disease did not reveal an association except response
to colchicine that was shown to be influenced by the MTHFR C677T mutation.
Behcet’s  disease  (BD),  first  described  in  1937  by
dermatologist Dr. Hulusi Behçet from Istanbul, is a chronic,
multisystem,  inflammatory  disorder  characterized  by
mucocutaneous, ocular, vascular, and central nervous system
manifestations. The common manifestations are recurrent oral
and genital ulcers and ocular inflammation. Venous or arterial
thromboses  occur  in  7%  to  38%  of  patients  [1].  Venous
thrombosis is more common than arterial thrombosis, with
relative  frequencies  of  90%  and  10%,  respectively  [2,3].
Colchicine is commonly used in the treatment of Behçet’s
disease;  however,  some  patients  are  unresponsive  to
colchicine treatment.
BD is endemically higher in Turkey and Japan. These
countries  have  populations  derived  historically  from  the
ancient Silk Road and have a prevalence of 80 to 370 cases
per 100,000 [4]. BD occurs more commonly in men than in
women and affects primarily individuals between the second
and fourth decades of life, with a more aggressive course in
young male adults. The leading cause of chronic morbidity is
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high, especially with ophthalmic inflammation, which can
eventually result in blindness.
Although  the  pathogenesis  of  BD  remains  poorly
understood, certain infectious and environmental factors are
able to trigger symptomatology in individuals with particular
genetic variants [5]. In common with ankylosing spondylitis
and psoriatic arthropathy, BD has major histocompatibility
complex  (MHC)  class  I  associations.  Human  leukocyte
antigen  HLA-B51  is  the  most  strongly  associated  known
genetic factor to BD [6]; however, it accounts for less than
20% of the genetic risk, even in familial cases (less than 5%),
which indicates that other genetic factors exist.
Methylene tetrahydrofolate reductase (MTHFR) is the
enzyme that catalyzes the transformation of homocysteine
(Hcy) to methionine via the remethylation pathway (gene
located in 1p36) [7]. Hyperhomocysteinemia (HHC), a known
prothrombotic  condition,  is  the  consequence  of  decreased
activity of MTHFR [8]. The C677T mutation of the MTHFR
gene, which causes an amino acid change from alanine to
valine,  is  associated  with  reduced  activity  and  increased
thermolability of the enzyme [9]. This mutation is considered
the most common genetic cause of elevated Hcy levels [10,
11] and could slightly increase the risk of arterial or venous
thrombosis [12,13]. HHC was repeatedly observed in BD
[14-17],  sometimes  with  a  positive  correlation  with
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1696thrombosis [14,16,18] and ocular involvement [15,17], which
is usually accompanied by retinal vaso-occlusive disease.
Our aim in this study was to investigate the MTHFR gene
C677T mutation in patients with BD and evaluate if there was
an association with clinical features, especially thrombosis, in
a relatively large cohort of patients with BD.
METHODS
Subjects: The study group consisted of 318 unrelated patients
with BD (160 male and 158 female; mean age and standard
deviation [SD] 36.57±9.485 years) and 207 unrelated healthy
controls  (82  male  and  125  female;  mean  age  and  SD
36.31±11.978  years).  BD  patients  were  gathered  from
different  clinics  (Ankara  Numune  Training  and  Research
Hospital  Second  Dermatology  Clinic,  Ankara,  Turkey
Department  of  Dermatology  and  Department  of  Physical
Therapy  and  Rehabilitation  of  Gaziosmanpasa  University,
Tokat,  Turkey)  and  fulfilled  the  International  Criteria  of
Behcet's Disease for classification [19]. All participants were
of Turkish origin from the central region of Turkey. The
healthy controls were matched in age and geographic area
with BD patients. The study protocol was approved by the
Local  Ethics  Committee  of  Gaziosmanpasa  University
Faculty  of  Medicine  and  written  informed  consent  was
obtained from the study participants.
Genotyping of MTHFR gene mutation: Genomic DNA was
extracted from EDTA-treated whole venous blood samples,
using  a  commercial  DNA  isolation  kit  (Sigma-Aldrich,
Taufkirchen, Germany). The MTHFR C677T mutation was
analyzed  by  PCR-based  restriction  fragment  length
polymorphism (RFLP) methods as described previously [8].
The PCR protocol consisted of an initial melting step of 5 min
at 94 °C; followed by 35 cycles of 30 s at 94 °C, 30 s at 61 °C,
and 30 s at 72 °C; and a final elongation step of 5 min at 72 °C.
PCR primers (5′-TGA AGG AGA AGG TGT CTG CGG
GA-3′ and 5′-AGG ACG GTG CGG TGA GAG TG-3′) were
used to amplify a portion of the MTHFR gene from 100 ng of
genomic DNA in a 25-µl reaction containing 2.5 µl of 10×
PCR buffer (Fermentas, Shenzhen, China), 200 µM dNTP
(Fermentas), 10 pM each of primers (MWG-Biotech AG,
Ebersberg, Germany), and one unit of Taq DNA polymerase
(Fermentas). After amplification, the 198-bp PCR product
was  digested  with  HinfI  (Fermentas)  in  a  15-µl  reaction
solution containing 10 µl of PCR product, 1.5 µl of 10× buffer,
and two units of HinfI at 37 °C overnight. The digestion
products were separated on 3% agarose gels, and fragments
stained  with  ethidium  bromide  were  photographed  on  an
ultraviolet  transilluminator.  Wild-type  individuals  were
identified by only a 198-bp fragment, heterozygotes by both
the 175/23-bp fragments, and homozygote variants (TT) by
the 175-bp fragment.
Statistical analysis: Statistical analysis was performed using
the Statistical Package for the Social Sciences (SPSS version
13.0, SPSS Inc., Chicago, IL) and the OpenEpi Info software
package version 2.2. Results were given as mean±standard
deviation (SD). The χ2 test was used to evaluate the Hardy–
Weinberg equilibrium for the distribution of the genotypes of
the patients and the controls. The relationships between the
C677T mutation and the clinical and demographics features
were analyzed by using the χ2 test or ANOVA (ANOVA)
statistics. The χ2 test and Fisher’s exact test were used to
compare categorical variables appropriately, and odds ratio
(OR) and 95% confidence interval (CI) were used for the
assessment of risk factors. All p values were 2-tailed, and CIs
were set at 95%. A p value less than 0.05 was considered
significant.
RESULTS
The baseline clinical and demographics features of the study
patients with BD are shown in Table 1. With one exception,
there  was  no  statistically  significant  association  observed
between clinical and demographic features of BD patients
(gender, age, disease duration, treatment duration, oral ulcers,
genital ulcers, ocular inflammation, deep venous thrombosis,
skin  lesions,  colchicine  use,  papulopustule,  erythema
nodosum) and the MTHFR gene C677T mutation. There was
a  statistically  significant  association  between  response  to
colchicine and the MTHFR C677T mutation in BD patients
(p=0.046; data not shown). Because BD is common in males,
we compared colchicine responsiveness with gender and no
association was found. The response to treatment was higher
in homozygous normal BD patients than heterozygous BD
patients  (65.5%  versus  29.1%).  Allelic  and  genotypic
distributions of the C677T mutation are shown in Table 2. The
observed and expected frequencies of the mutation in both
patient  and  control  groups  were  in  Hardy–Weinberg
equilibrium. The genotype and allele frequencies of C677T
mutation showed a statistically significant difference between
BD patients and controls (p=0.003 and p=0.001, respectively;
OR  1.7,  95%  CI  1.23–2.35).  Although  the  frequency  of
heterozygosity of C677T was nearly similar between two
groups, the homozygosity of C677T was significantly higher
in BD patients than healthy controls (p=0.004; OR 5.05, 95%
CI: 1.49–17.11).
DISCUSSION
In our study we found a high association between BD and the
MTHFR  gene  C677T  mutation.  In  other  studies  of  the
MTHFR C677T mutation and BD in the Turkish population,
such a significant association has not been reported [20,21].
Ozkul  et  al.  found  equal  frequencies  of  MTHFR  C677T
polymorphism overall in 59 patients and 42 healthy controls
[21].  Although  in  their  study  the  frequency  of  the  TT
homozygous genotype was higher in patients than in controls,
the difference was statistically not significant. Canataroglu et
al.  reported  the  frequencies  of  homozygosity  for  the
MTHFR C677T mutation as 7.5% and 10% in BD patient and
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1697control  groups  (p>0.05),  respectively,  from  the  southern
region of Turkey (40 BD patients and 60 healthy controls)
[20]. There was no concordance between our results and the
results of other studies of the Turkish population, perhaps
because of the low patient and control populations of these
studies compared to ours. No relation was found between the
MTHFR C677T mutation and BD in reports of small study
populations  from  Spain  [22,23].  In  concordance  with  our
study, homozygosity of the T allele of the MTHFR gene was
found to be prevalent in BD patients in a Tunisian population
(35 BD patients were compared to 39 healthy volunteers)
[24]. Our study is the first study that has investigated the
association between the MTHFR C677T mutation and BD in
a large study population.
With  one  exception,  no  statistically  significant
association was observed in our study between clinical and
demographic features of BD patients (gender, age, disease
duration, treatment duration, oral ulcers, genital ulcers, ocular
inflammation, DVT [deep venous thrombosis], skin lesions,
colchicine use, papulopustule, erythema nodosum) and the
MTHFR  gene  C677T  mutation.  Many  previous  studies
focused on the genotype distribution of MTHFR C677T of BD
patients with and without DVT. While one study reported an
association  between  thrombosis  and  the  MTHFR  C677T
mutation in BD patients [20], no association was found in the
others [22-28]. The MTHFR C677T mutation was also shown
to have an association with ocular involvement in BD patients
[21], but this was not confirmed by another study [29].
In our study, we found a significant association between
response to colchicine and the MTHFR C677T mutation in
BD patients (p=0.046); this has not been observed in other
studies.  Colchicine,  commonly  used  in  the  treatment  of
Behçet’s disease and other inflammatory diseases, inhibits
neutrophil chemotaxis, resulting in a decreased number in the
inflamed area, thereby preventing exacerbation of the disease
[30]. However, some patients are unresponsive to colchicine
treatment in BD and other inflammatory diseases. Colchicine
unresponsiveness  was  studied  in  Familial  Mediterranean
Fever  (FMF)  patients  with  different  genes.  For  example,
C3435T polymorphism in exon 26 of multpile drug resistance
1 (MDR1) gene was associated with colchicine resistance in
nonresponder  FMF  patients  during  the  common  therapy
protocol  [31].  Soylemezoglu  et  al.  [32]  reported  that  the
M694V/M694V  mutation  of  the  Mediterranean  fever
(MEFV) gene is associated with a lower response to colchicine
treatment. In the literature, colchicine efficacy was not found
to be the same for female and male patients [33], but in our
TABLE 1. BASELINE CLINICAL AND DEMOGRAPHICS FEATURES OF THE STUDY PATIENTS WITH BD.
Characteristic Study group
Gender, number male/female (male % /female %) 160/158 (50.3/49.7)
Age, mean±SD (range) years 36.57±9.485
Disease duration, mean±SD (range) years 7.09±6.601
Treatment duration, mean±SD (range) years 5.64±6.588
Oral ulcers, n (%) 216/218 (99.1)
Genital ulcers, n (%) 164/218 (75.2)
Ocular inflammation, n (%) 89/210 (42.4)
Deep venous thrombosis (DVT), n (%) 41/210 (19.5)
Skin lesions, n (%) 96/210 (45.7)
Colchicine use, n (%) 216/218 (99.1)
Response to colchicine, n (%) 165/215 (76.7)
Papulopustule, n (%) 125/218 (57.3)
Erythema nodosum, n (%) 84/218 (38.5)
TABLE 2. GENOTYPE AND ALLELE FREQUENCIES OF MTHFR GENE C677T POLYMORPHISMS IN PATIENT AND CONTROL GROUPS.
MTHFR C677T BD patients n (%) Healthy controls n (%) p OR (CI 95%)
Genotypes
CC 189 (59.4) 146 (70.5) 0.003  
CT 107 (33.6) 58 (28.0)    
TT 22 (6.9) 3 (1.4)    
CC+CT: TT 296: 22 204: 3 0.004 5.05 (1.49–17.11)
CC: CT+TT 189: 129 146: 61 0.009 1.63 (1.13–2.38)
Alleles
C 485 (76.3) 350 (84.5) 0.001 1.70 (1.23–2.35)
T 151 (23.7) 64 (15.5)    
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between gender.
In patients with MTHFR mutations, folate metabolism is
affected in several ways. Specifically, the methylation cycle
seems to be impaired; reduced enzyme activity and decreased
remethylation of Hcy to methionine lead to elevated total Hcy
and  reduced  de  novo  methyl  group  supply  for
transmethylation  reactions.  Moreover,  altered  Th1/Th2  (T
helper  1/2)  balance  resulting  from  inhibition  of  the
remethylation cycle is speculated to cause abnormal cellular
immune response in relevant patients [34]. Because of this
effect on immune response, unresponsiveness to colchicine
may occur in MTHFR mutation carriers.
Although in this study we hoped to find an association
between  DVT  in  BD  patients  and  the  MTHFR  C677T
mutation,  surprisingly  we  found  an  association  between
response  to  colchicine  treatment  of  BD  patients  and  the
MTHFR C677T mutation. This is an important result that must
be confirmed by other studies not only in BD but also in other
inflammatory disorders using colchicine for treatment. Last
but not least, if our observation can be substantiated with
further studies, evaluation for MTHFR mutations and perhaps
folate supplementation may become necessary in selected
patients.
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